Loading...
Docoh

Theralink (THER)

Press releases

From Benzinga Pro
Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
19 Apr 22
Small Cap, Press Releases
Theralink currently supports preclinical and clinical studies across 11 biopharma clients, including multinational corporations Ongoing discussions with existing clients for development of Companion Diagnostics, a large
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
28 Mar 22
News, Contracts, Small Cap, Press Releases
Theralink's RPPA (Reverse Phase Protein Array) Technology to be deployed to support and enhance Genomic insights and may ultimately help improve patient care SIOUX FALLS, S.D. and DENVER, March 28, 2022
Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
21 Mar 22
Press Releases
DENVER, March 21, 2022 /PRNewswire/ -- Theralink Technologies (OTC:THER) ("Theralink" or the "Company"), a precision medicine company with a patented, novel phosphoprotein-based assay for breast cancer
Early Results Show >90% Actionability and >75% Clinical Utility for Theralink® Technologies' Lab Developed Test for Advanced Breast Cancer Patients
14 Mar 22
Small Cap, Press Releases
DENVER, March 14, 2022 /PRNewswire/ -- Theralink Technologies (OTC:THER) ("Theralink" or the "Company"), a precision oncology molecular profiling company with a patented, novel phosphoprotein-based assay